Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Current Assets (2020 - 2025)

Barinthus Biotherapeutics' Current Assets history spans 6 years, with the latest figure at $77.8 million for Q4 2025.

  • For Q4 2025, Current Assets fell 38.14% year-over-year to $77.8 million; the TTM value through Dec 2025 reached $77.8 million, down 38.14%, while the annual FY2025 figure was $77.8 million, 38.14% down from the prior year.
  • Current Assets reached $77.8 million in Q4 2025 per BRNS's latest filing, down from $86.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $256.7 million in Q2 2021 to a low of $77.8 million in Q4 2025.
  • Average Current Assets over 5 years is $170.3 million, with a median of $167.2 million recorded in 2021.
  • Peak YoY movement for Current Assets: skyrocketed 373.4% in 2021, then plummeted 38.14% in 2025.
  • A 5-year view of Current Assets shows it stood at $226.8 million in 2021, then fell by 6.05% to $213.0 million in 2022, then dropped by 26.35% to $156.9 million in 2023, then decreased by 19.86% to $125.7 million in 2024, then crashed by 38.14% to $77.8 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Current Assets are $77.8 million (Q4 2025), $86.8 million (Q3 2025), and $100.4 million (Q2 2025).